aTYR PHARMA INC — Director's Dealing 2020

Feb 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2020-02-05

Reporting Person: Broadfoot Jill Marie (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-06	Common stock	M	893	—	Acquired	7500	Direct
2020-02-07	Common stock	S	375	$4.03	Disposed	7125	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-05	Employee Stock Option (right to buy)	$4.39	A	23359	Acquired	2030-02-05	Common Stock (23359)	Direct
2020-02-06	Restricted Stock Unit	$	M	893	Disposed		Common Stock (893)	Direct

Footnotes

F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: Includes 718 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 16, 2019.

F4: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 6, 2019.

F5: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 5, 2020, such that this option will be fully exercisable on February 5, 2024. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.

F6: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020.